Investigator Initiated Clinical Trial on the Tolerance, Safety and Preliminary Efficacy of KSH01-TCRT Injection in Solid Tumor Subjects
Latest Information Update: 06 Apr 2023
At a glance
- Drugs KSH 01 (Primary)
- Indications Bladder cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors TCRx Therapeutics
- 29 Mar 2023 Status changed from not yet recruiting to recruiting.
- 17 Oct 2022 New trial record